Pulmonary Surfactant Industry Research Report 2025
Description
Summary
According to APO Research, the global Pulmonary Surfactant market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Pulmonary Surfactant is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Pulmonary Surfactant is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Pulmonary Surfactant is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Pulmonary Surfactant include Abbott, Nanjing Norris Pharm Technology, AbbVie, XpressBio, Windtree Therapeutics, Tekzima (Noargen), Reddot Biotech, ONY Biotech and Lyomark Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Pulmonary Surfactant, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pulmonary Surfactant.
The report will help the Pulmonary Surfactant manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Pulmonary Surfactant market size, estimations, and forecasts are provided in terms of sales volume (k units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Pulmonary Surfactant market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Pulmonary Surfactant Segment by Company
Abbott Nanjing Norris Pharm Technology AbbVie XpressBio Windtree Therapeutics Tekzima (Noargen) Reddot Biotech ONY Biotech Lyomark Pharma LSBio Creative Diagnostics Boehringer Ingelheim Biorbyt Biomatik Aviva Systems BiologyPulmonary Surfactant Segment by Type
Synthetic Pulmonary Surfactants Animal Derived SurfactantsPulmonary Surfactant Segment by Application
Hospital laboratory OthersPulmonary Surfactant Segment by Region
North America United States Canada Mexico Europe Germany France U.K. Italy Russia Spain Netherlands Switzerland Sweden Poland Asia-Pacific China Japan South Korea India Australia Taiwan Southeast Asia South America Brazil Argentina Chile Middle East & Africa Egypt South Africa Israel Türkiye GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Surfactant market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Surfactant and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Surfactant.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Pulmonary Surfactant manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Pulmonary Surfactant by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Pulmonary Surfactant in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
According to APO Research, the global Pulmonary Surfactant market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Pulmonary Surfactant is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Pulmonary Surfactant is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Pulmonary Surfactant is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Pulmonary Surfactant include Abbott, Nanjing Norris Pharm Technology, AbbVie, XpressBio, Windtree Therapeutics, Tekzima (Noargen), Reddot Biotech, ONY Biotech and Lyomark Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Pulmonary Surfactant, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pulmonary Surfactant.
The report will help the Pulmonary Surfactant manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Pulmonary Surfactant market size, estimations, and forecasts are provided in terms of sales volume (k units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Pulmonary Surfactant market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Pulmonary Surfactant Segment by Company
Abbott Nanjing Norris Pharm Technology AbbVie XpressBio Windtree Therapeutics Tekzima (Noargen) Reddot Biotech ONY Biotech Lyomark Pharma LSBio Creative Diagnostics Boehringer Ingelheim Biorbyt Biomatik Aviva Systems BiologyPulmonary Surfactant Segment by Type
Synthetic Pulmonary Surfactants Animal Derived SurfactantsPulmonary Surfactant Segment by Application
Hospital laboratory OthersPulmonary Surfactant Segment by Region
North America United States Canada Mexico Europe Germany France U.K. Italy Russia Spain Netherlands Switzerland Sweden Poland Asia-Pacific China Japan South Korea India Australia Taiwan Southeast Asia South America Brazil Argentina Chile Middle East & Africa Egypt South Africa Israel Türkiye GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Surfactant market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Surfactant and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Surfactant.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Pulmonary Surfactant manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Pulmonary Surfactant by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Pulmonary Surfactant in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
Table of Contents
137 Pages
- 1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
- 2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Pulmonary Surfactant Market Size (2020-2031)
- 2.2.2 Global Pulmonary Surfactant Sales (2020-2031)
- 2.2.3 Global Pulmonary Surfactant Market Average Price (2020-2031)
- 2.3 Pulmonary Surfactant by Type
- 2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- 2.3.2 Synthetic Pulmonary Surfactants
- 2.3.3 Animal Derived Surfactants
- 2.4 Pulmonary Surfactant by Application
- 2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
- 2.4.2 Hospital
- 2.4.3 laboratory
- 2.4.4 Others
- 3 Market Competitive Landscape by Manufacturers
- 3.1 Global Pulmonary Surfactant Market Competitive Situation by Manufacturers (2020 Versus 2024)
- 3.2 Global Pulmonary Surfactant Sales (k units) of Manufacturers (2020-2025)
- 3.3 Global Pulmonary Surfactant Revenue of Manufacturers (2020-2025)
- 3.4 Global Pulmonary Surfactant Average Price by Manufacturers (2020-2025)
- 3.5 Global Pulmonary Surfactant Industry Ranking, 2023 VS 2024 VS 2025
- 3.6 Global Manufacturers of Pulmonary Surfactant, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Pulmonary Surfactant, Product Type & Application
- 3.8 Global Manufacturers of Pulmonary Surfactant, Established Date
- 3.9 Global Pulmonary Surfactant Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
- 4 Manufacturers Profiled
- 4.1 Abbott
- 4.1.1 Abbott Company Information
- 4.1.2 Abbott Business Overview
- 4.1.3 Abbott Pulmonary Surfactant Sales, Revenue and Gross Margin (2020-2025)
- 4.1.4 Abbott Pulmonary Surfactant Product Portfolio
- 4.1.5 Abbott Recent Developments
- 4.2 Nanjing Norris Pharm Technology
- 4.2.1 Nanjing Norris Pharm Technology Company Information
- 4.2.2 Nanjing Norris Pharm Technology Business Overview
- 4.2.3 Nanjing Norris Pharm Technology Pulmonary Surfactant Sales, Revenue and Gross Margin (2020-2025)
- 4.2.4 Nanjing Norris Pharm Technology Pulmonary Surfactant Product Portfolio
- 4.2.5 Nanjing Norris Pharm Technology Recent Developments
- 4.3 AbbVie
- 4.3.1 AbbVie Company Information
- 4.3.2 AbbVie Business Overview
- 4.3.3 AbbVie Pulmonary Surfactant Sales, Revenue and Gross Margin (2020-2025)
- 4.3.4 AbbVie Pulmonary Surfactant Product Portfolio
- 4.3.5 AbbVie Recent Developments
- 4.4 XpressBio
- 4.4.1 XpressBio Company Information
- 4.4.2 XpressBio Business Overview
- 4.4.3 XpressBio Pulmonary Surfactant Sales, Revenue and Gross Margin (2020-2025)
- 4.4.4 XpressBio Pulmonary Surfactant Product Portfolio
- 4.4.5 XpressBio Recent Developments
- 4.5 Windtree Therapeutics
- 4.5.1 Windtree Therapeutics Company Information
- 4.5.2 Windtree Therapeutics Business Overview
- 4.5.3 Windtree Therapeutics Pulmonary Surfactant Sales, Revenue and Gross Margin (2020-2025)
- 4.5.4 Windtree Therapeutics Pulmonary Surfactant Product Portfolio
- 4.5.5 Windtree Therapeutics Recent Developments
- 4.6 Tekzima (Noargen)
- 4.6.1 Tekzima (Noargen) Company Information
- 4.6.2 Tekzima (Noargen) Business Overview
- 4.6.3 Tekzima (Noargen) Pulmonary Surfactant Sales, Revenue and Gross Margin (2020-2025)
- 4.6.4 Tekzima (Noargen) Pulmonary Surfactant Product Portfolio
- 4.6.5 Tekzima (Noargen) Recent Developments
- 4.7 Reddot Biotech
- 4.7.1 Reddot Biotech Company Information
- 4.7.2 Reddot Biotech Business Overview
- 4.7.3 Reddot Biotech Pulmonary Surfactant Sales, Revenue and Gross Margin (2020-2025)
- 4.7.4 Reddot Biotech Pulmonary Surfactant Product Portfolio
- 4.7.5 Reddot Biotech Recent Developments
- 4.8 ONY Biotech
- 4.8.1 ONY Biotech Company Information
- 4.8.2 ONY Biotech Business Overview
- 4.8.3 ONY Biotech Pulmonary Surfactant Sales, Revenue and Gross Margin (2020-2025)
- 4.8.4 ONY Biotech Pulmonary Surfactant Product Portfolio
- 4.8.5 ONY Biotech Recent Developments
- 4.9 Lyomark Pharma
- 4.9.1 Lyomark Pharma Company Information
- 4.9.2 Lyomark Pharma Business Overview
- 4.9.3 Lyomark Pharma Pulmonary Surfactant Sales, Revenue and Gross Margin (2020-2025)
- 4.9.4 Lyomark Pharma Pulmonary Surfactant Product Portfolio
- 4.9.5 Lyomark Pharma Recent Developments
- 4.10 LSBio
- 4.10.1 LSBio Company Information
- 4.10.2 LSBio Business Overview
- 4.10.3 LSBio Pulmonary Surfactant Sales, Revenue and Gross Margin (2020-2025)
- 4.10.4 LSBio Pulmonary Surfactant Product Portfolio
- 4.10.5 LSBio Recent Developments
- 4.11 Creative Diagnostics
- 4.11.1 Creative Diagnostics Company Information
- 4.11.2 Creative Diagnostics Business Overview
- 4.11.3 Creative Diagnostics Pulmonary Surfactant Sales, Revenue and Gross Margin (2020-2025)
- 4.11.4 Creative Diagnostics Pulmonary Surfactant Product Portfolio
- 4.11.5 Creative Diagnostics Recent Developments
- 4.12 Boehringer Ingelheim
- 4.12.1 Boehringer Ingelheim Company Information
- 4.12.2 Boehringer Ingelheim Business Overview
- 4.12.3 Boehringer Ingelheim Pulmonary Surfactant Sales, Revenue and Gross Margin (2020-2025)
- 4.12.4 Boehringer Ingelheim Pulmonary Surfactant Product Portfolio
- 4.12.5 Boehringer Ingelheim Recent Developments
- 4.13 Biorbyt
- 4.13.1 Biorbyt Company Information
- 4.13.2 Biorbyt Business Overview
- 4.13.3 Biorbyt Pulmonary Surfactant Sales, Revenue and Gross Margin (2020-2025)
- 4.13.4 Biorbyt Pulmonary Surfactant Product Portfolio
- 4.13.5 Biorbyt Recent Developments
- 4.14 Biomatik
- 4.14.1 Biomatik Company Information
- 4.14.2 Biomatik Business Overview
- 4.14.3 Biomatik Pulmonary Surfactant Sales, Revenue and Gross Margin (2020-2025)
- 4.14.4 Biomatik Pulmonary Surfactant Product Portfolio
- 4.14.5 Biomatik Recent Developments
- 4.15 Aviva Systems Biology
- 4.15.1 Aviva Systems Biology Company Information
- 4.15.2 Aviva Systems Biology Business Overview
- 4.15.3 Aviva Systems Biology Pulmonary Surfactant Sales, Revenue and Gross Margin (2020-2025)
- 4.15.4 Aviva Systems Biology Pulmonary Surfactant Product Portfolio
- 4.15.5 Aviva Systems Biology Recent Developments
- 5 Global Pulmonary Surfactant Market Scenario by Region
- 5.1 Global Pulmonary Surfactant Market Size by Region: 2020 VS 2024 VS 2031
- 5.2 Global Pulmonary Surfactant Sales by Region: 2020-2031
- 5.2.1 Global Pulmonary Surfactant Sales by Region: 2020-2025
- 5.2.2 Global Pulmonary Surfactant Sales by Region: 2026-2031
- 5.3 Global Pulmonary Surfactant Revenue by Region: 2020-2031
- 5.3.1 Global Pulmonary Surfactant Revenue by Region: 2020-2025
- 5.3.2 Global Pulmonary Surfactant Revenue by Region: 2026-2031
- 5.4 North America Pulmonary Surfactant Market Facts & Figures by Country
- 5.4.1 North America Pulmonary Surfactant Market Size by Country: 2020 VS 2024 VS 2031
- 5.4.2 North America Pulmonary Surfactant Sales by Country (2020-2031)
- 5.4.3 North America Pulmonary Surfactant Revenue by Country (2020-2031)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Pulmonary Surfactant Market Facts & Figures by Country
- 5.5.1 Europe Pulmonary Surfactant Market Size by Country: 2020 VS 2024 VS 2031
- 5.5.2 Europe Pulmonary Surfactant Sales by Country (2020-2031)
- 5.5.3 Europe Pulmonary Surfactant Revenue by Country (2020-2031)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Pulmonary Surfactant Market Facts & Figures by Country
- 5.6.1 Asia Pacific Pulmonary Surfactant Market Size by Country: 2020 VS 2024 VS 2031
- 5.6.2 Asia Pacific Pulmonary Surfactant Sales by Country (2020-2031)
- 5.6.3 Asia Pacific Pulmonary Surfactant Revenue by Country (2020-2031)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Pulmonary Surfactant Market Facts & Figures by Country
- 5.7.1 South America Pulmonary Surfactant Market Size by Country: 2020 VS 2024 VS 2031
- 5.7.2 South America Pulmonary Surfactant Sales by Country (2020-2031)
- 5.7.3 South America Pulmonary Surfactant Revenue by Country (2020-2031)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Pulmonary Surfactant Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Pulmonary Surfactant Market Size by Country: 2020 VS 2024 VS 2031
- 5.8.2 Middle East and Africa Pulmonary Surfactant Sales by Country (2020-2031)
- 5.8.3 Middle East and Africa Pulmonary Surfactant Revenue by Country (2020-2031)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
- 6 Segment by Type
- 6.1 Global Pulmonary Surfactant Sales by Type (2020-2031)
- 6.1.1 Global Pulmonary Surfactant Sales by Type (2020-2031) & (k units)
- 6.1.2 Global Pulmonary Surfactant Sales Market Share by Type (2020-2031)
- 6.2 Global Pulmonary Surfactant Revenue by Type (2020-2031)
- 6.2.1 Global Pulmonary Surfactant Sales by Type (2020-2031) & (US$ Million)
- 6.2.2 Global Pulmonary Surfactant Revenue Market Share by Type (2020-2031)
- 6.3 Global Pulmonary Surfactant Price by Type (2020-2031)
- 7 Segment by Application
- 7.1 Global Pulmonary Surfactant Sales by Application (2020-2031)
- 7.1.1 Global Pulmonary Surfactant Sales by Application (2020-2031) & (k units)
- 7.1.2 Global Pulmonary Surfactant Sales Market Share by Application (2020-2031)
- 7.2 Global Pulmonary Surfactant Revenue by Application (2020-2031)
- 7.2.1 Global Pulmonary Surfactant Sales by Application (2020-2031) & (US$ Million)
- 7.2.2 Global Pulmonary Surfactant Revenue Market Share by Application (2020-2031)
- 7.3 Global Pulmonary Surfactant Price by Application (2020-2031)
- 8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Pulmonary Surfactant Value Chain Analysis
- 8.1.1 Pulmonary Surfactant Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Pulmonary Surfactant Production Mode & Process
- 8.2 Pulmonary Surfactant Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Pulmonary Surfactant Distributors
- 8.2.3 Pulmonary Surfactant Customers
- 9 Global Pulmonary Surfactant Analyzing Market Dynamics
- 9.1 Pulmonary Surfactant Industry Trends
- 9.2 Pulmonary Surfactant Industry Drivers
- 9.3 Pulmonary Surfactant Industry Opportunities and Challenges
- 9.4 Pulmonary Surfactant Industry Restraints
- 10 Report Conclusion
- 11 Disclaimer
- List of Tables
- Table 1. Secondary Sources
- Table 2. Primary Sources
- Table 3. Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- Table 4. Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million)
- Table 5. Global Pulmonary Surfactant Volume and Revenue Market Size and CAGR of Manufacturers (2020 Versus 2024)
- Table 6. Global Pulmonary Surfactant Sales (k units) of Manufacturers (2020-2025)
- Table 7. Global Pulmonary Surfactant Sales Market Share by Manufacturers (2020-2025)
- Table 8. Global Pulmonary Surfactant Revenue of Manufacturers (2020-2025)
- Table 9. Global Pulmonary Surfactant Revenue Share by Manufacturers (2020-2025)
- Table 10. Global Market Pulmonary Surfactant Average Price (US$/unit) of Manufacturers (2020-2025)
- Table 11. Global Pulmonary Surfactant Industry Ranking, 2023 VS 2024 VS 2025
- Table 12. Global Manufacturers of Pulmonary Surfactant, Manufacturing Sites & Headquarters
- Table 13. Global Manufacturers of Pulmonary Surfactant, Product Type & Application
- Table 14. Global Pulmonary Surfactant Manufacturers Established Date
- Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 16. Global Pulmonary Surfactant by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024)
- Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
- Table 18. Abbott Company Information
- Table 19. Abbott Business Overview
- Table 20. Abbott Pulmonary Surfactant Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 21. Abbott Pulmonary Surfactant Product Portfolio
- Table 22. Abbott Recent Developments
- Table 23. Nanjing Norris Pharm Technology Company Information
- Table 24. Nanjing Norris Pharm Technology Business Overview
- Table 25. Nanjing Norris Pharm Technology Pulmonary Surfactant Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 26. Nanjing Norris Pharm Technology Pulmonary Surfactant Product Portfolio
- Table 27. Nanjing Norris Pharm Technology Recent Developments
- Table 28. AbbVie Company Information
- Table 29. AbbVie Business Overview
- Table 30. AbbVie Pulmonary Surfactant Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 31. AbbVie Pulmonary Surfactant Product Portfolio
- Table 32. AbbVie Recent Developments
- Table 33. XpressBio Company Information
- Table 34. XpressBio Business Overview
- Table 35. XpressBio Pulmonary Surfactant Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 36. XpressBio Pulmonary Surfactant Product Portfolio
- Table 37. XpressBio Recent Developments
- Table 38. Windtree Therapeutics Company Information
- Table 39. Windtree Therapeutics Business Overview
- Table 40. Windtree Therapeutics Pulmonary Surfactant Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 41. Windtree Therapeutics Pulmonary Surfactant Product Portfolio
- Table 42. Windtree Therapeutics Recent Developments
- Table 43. Tekzima (Noargen) Company Information
- Table 44. Tekzima (Noargen) Business Overview
- Table 45. Tekzima (Noargen) Pulmonary Surfactant Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 46. Tekzima (Noargen) Pulmonary Surfactant Product Portfolio
- Table 47. Tekzima (Noargen) Recent Developments
- Table 48. Reddot Biotech Company Information
- Table 49. Reddot Biotech Business Overview
- Table 50. Reddot Biotech Pulmonary Surfactant Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 51. Reddot Biotech Pulmonary Surfactant Product Portfolio
- Table 52. Reddot Biotech Recent Developments
- Table 53. ONY Biotech Company Information
- Table 54. ONY Biotech Business Overview
- Table 55. ONY Biotech Pulmonary Surfactant Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 56. ONY Biotech Pulmonary Surfactant Product Portfolio
- Table 57. ONY Biotech Recent Developments
- Table 58. Lyomark Pharma Company Information
- Table 59. Lyomark Pharma Business Overview
- Table 60. Lyomark Pharma Pulmonary Surfactant Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 61. Lyomark Pharma Pulmonary Surfactant Product Portfolio
- Table 62. Lyomark Pharma Recent Developments
- Table 63. LSBio Company Information
- Table 64. LSBio Business Overview
- Table 65. LSBio Pulmonary Surfactant Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 66. LSBio Pulmonary Surfactant Product Portfolio
- Table 67. LSBio Recent Developments
- Table 68. Creative Diagnostics Company Information
- Table 69. Creative Diagnostics Business Overview
- Table 70. Creative Diagnostics Pulmonary Surfactant Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 71. Creative Diagnostics Pulmonary Surfactant Product Portfolio
- Table 72. Creative Diagnostics Recent Developments
- Table 73. Boehringer Ingelheim Company Information
- Table 74. Boehringer Ingelheim Business Overview
- Table 75. Boehringer Ingelheim Pulmonary Surfactant Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 76. Boehringer Ingelheim Pulmonary Surfactant Product Portfolio
- Table 77. Boehringer Ingelheim Recent Developments
- Table 78. Biorbyt Company Information
- Table 79. Biorbyt Business Overview
- Table 80. Biorbyt Pulmonary Surfactant Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 81. Biorbyt Pulmonary Surfactant Product Portfolio
- Table 82. Biorbyt Recent Developments
- Table 83. Biomatik Company Information
- Table 84. Biomatik Business Overview
- Table 85. Biomatik Pulmonary Surfactant Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 86. Biomatik Pulmonary Surfactant Product Portfolio
- Table 87. Biomatik Recent Developments
- Table 88. Aviva Systems Biology Company Information
- Table 89. Aviva Systems Biology Business Overview
- Table 90. Aviva Systems Biology Pulmonary Surfactant Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 91. Aviva Systems Biology Pulmonary Surfactant Product Portfolio
- Table 92. Aviva Systems Biology Recent Developments
- Table 93. Global Pulmonary Surfactant Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
- Table 94. Global Pulmonary Surfactant Sales by Region (2020-2025) & (k units)
- Table 95. Global Pulmonary Surfactant Sales Market Share by Region (2020-2025)
- Table 96. Global Pulmonary Surfactant Sales by Region (2026-2031) & (k units)
- Table 97. Global Pulmonary Surfactant Sales Market Share by Region (2026-2031)
- Table 98. Global Pulmonary Surfactant Revenue by Region (2020-2025) & (US$ Million)
- Table 99. Global Pulmonary Surfactant Revenue Market Share by Region (2020-2025)
- Table 100. Global Pulmonary Surfactant Revenue by Region (2026-2031) & (US$ Million)
- Table 101. Global Pulmonary Surfactant Revenue Market Share by Region (2026-2031)
- Table 102. North America Pulmonary Surfactant Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 103. North America Pulmonary Surfactant Sales by Country (2020-2025) & (k units)
- Table 104. North America Pulmonary Surfactant Sales by Country (2026-2031) & (k units)
- Table 105. North America Pulmonary Surfactant Revenue by Country (2020-2025) & (US$ Million)
- Table 106. North America Pulmonary Surfactant Revenue by Country (2026-2031) & (US$ Million)
- Table 107. Europe Pulmonary Surfactant Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 108. Europe Pulmonary Surfactant Sales by Country (2020-2025) & (k units)
- Table 109. Europe Pulmonary Surfactant Sales by Country (2026-2031) & (k units)
- Table 110. Europe Pulmonary Surfactant Revenue by Country (2020-2025) & (US$ Million)
- Table 111. Europe Pulmonary Surfactant Revenue by Country (2026-2031) & (US$ Million)
- Table 112. Asia Pacific Pulmonary Surfactant Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 113. Asia Pacific Pulmonary Surfactant Sales by Country (2020-2025) & (k units)
- Table 114. Asia Pacific Pulmonary Surfactant Sales by Country (2026-2031) & (k units)
- Table 115. Asia Pacific Pulmonary Surfactant Revenue by Country (2020-2025) & (US$ Million)
- Table 116. Asia Pacific Pulmonary Surfactant Revenue by Country (2026-2031) & (US$ Million)
- Table 117. South America Pulmonary Surfactant Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 118. South America Pulmonary Surfactant Sales by Country (2020-2025) & (k units)
- Table 119. South America Pulmonary Surfactant Sales by Country (2026-2031) & (k units)
- Table 120. South America Pulmonary Surfactant Revenue by Country (2020-2025) & (US$ Million)
- Table 121. South America Pulmonary Surfactant Revenue by Country (2026-2031) & (US$ Million)
- Table 122. Middle East and Africa Pulmonary Surfactant Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 123. Middle East and Africa Pulmonary Surfactant Sales by Country (2020-2025) & (k units)
- Table 124. Middle East and Africa Pulmonary Surfactant Sales by Country (2026-2031) & (k units)
- Table 125. Middle East and Africa Pulmonary Surfactant Revenue by Country (2020-2025) & (US$ Million)
- Table 126. Middle East and Africa Pulmonary Surfactant Revenue by Country (2026-2031) & (US$ Million)
- Table 127. Global Pulmonary Surfactant Sales by Type (2020-2025) & (k units)
- Table 128. Global Pulmonary Surfactant Sales by Type (2026-2031) & (k units)
- Table 129. Global Pulmonary Surfactant Sales Market Share by Type (2020-2025)
- Table 130. Global Pulmonary Surfactant Sales Market Share by Type (2026-2031)
- Table 131. Global Pulmonary Surfactant Revenue by Type (2020-2025) & (US$ Million)
- Table 132. Global Pulmonary Surfactant Revenue by Type (2026-2031) & (US$ Million)
- Table 133. Global Pulmonary Surfactant Revenue Market Share by Type (2020-2025)
- Table 134. Global Pulmonary Surfactant Revenue Market Share by Type (2026-2031)
- Table 135. Global Pulmonary Surfactant Price by Type (2020-2025) & (US$/unit)
- Table 136. Global Pulmonary Surfactant Price by Type (2026-2031) & (US$/unit)
- Table 137. Global Pulmonary Surfactant Sales by Application (2020-2025) & (k units)
- Table 138. Global Pulmonary Surfactant Sales by Application (2026-2031) & (k units)
- Table 139. Global Pulmonary Surfactant Sales Market Share by Application (2020-2025)
- Table 140. Global Pulmonary Surfactant Sales Market Share by Application (2026-2031)
- Table 141. Global Pulmonary Surfactant Revenue by Application (2020-2025) & (US$ Million)
- Table 142. Global Pulmonary Surfactant Revenue by Application (2026-2031) & (US$ Million)
- Table 143. Global Pulmonary Surfactant Revenue Market Share by Application (2020-2025)
- Table 144. Global Pulmonary Surfactant Revenue Market Share by Application (2026-2031)
- Table 145. Global Pulmonary Surfactant Price by Application (2020-2025) & (US$/unit)
- Table 146. Global Pulmonary Surfactant Price by Application (2026-2031) & (US$/unit)
- Table 147. Key Raw Materials
- Table 148. Raw Materials Key Suppliers
- Table 149. Pulmonary Surfactant Distributors List
- Table 150. Pulmonary Surfactant Customers List
- Table 151. Pulmonary Surfactant Industry Trends
- Table 152. Pulmonary Surfactant Industry Drivers
- Table 153. Pulmonary Surfactant Industry Restraints
- Table 154. Authors List of This Report
- List of Figures
- Figure 1. Research Methodology
- Figure 2. Research Process
- Figure 3. Key Executives Interviewed
- Figure 4. Pulmonary Surfactant Product Image
- Figure 5. Global Pulmonary Surfactant Revenue (US$ Million), 2020 VS 2024 VS 2031
- Figure 6. Global Pulmonary Surfactant Market Size (2020-2031) & (US$ Million)
- Figure 7. Global Pulmonary Surfactant Sales (2020-2031) & (k units)
- Figure 8. Global Pulmonary Surfactant Average Price (US$/unit) & (2020-2031)
- Figure 9. Synthetic Pulmonary Surfactants Product Image
- Figure 10. Animal Derived Surfactants Product Image
- Figure 11. Hospital Product Image
- Figure 12. laboratory Product Image
- Figure 13. Others Product Image
- Figure 14. Global Pulmonary Surfactant Revenue Share by Manufacturers in 2024
- Figure 15. Global Manufacturers of Pulmonary Surfactant, Manufacturing Sites & Headquarters
- Figure 16. Global Top 5 and 10 Pulmonary Surfactant Players Market Share by Revenue in 2024
- Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
- Figure 18. Global Pulmonary Surfactant Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
- Figure 19. Global Pulmonary Surfactant Sales by Region in 2024
- Figure 20. Global Pulmonary Surfactant Revenue by Region in 2024
- Figure 21. North America Pulmonary Surfactant Market Size by Country in 2024
- Figure 22. North America Pulmonary Surfactant Sales Market Share by Country (2020-2031)
- Figure 23. North America Pulmonary Surfactant Revenue Market Share by Country (2020-2031)
- Figure 24. United States Pulmonary Surfactant Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 25. Canada Pulmonary Surfactant Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 26. Mexico Pulmonary Surfactant Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 27. Europe Pulmonary Surfactant Market Size by Country in 2024
- Figure 28. Europe Pulmonary Surfactant Sales Market Share by Country (2020-2031)
- Figure 29. Europe Pulmonary Surfactant Revenue Market Share by Country (2020-2031)
- Figure 30. Germany Pulmonary Surfactant Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 31. France Pulmonary Surfactant Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 32. U.K. Pulmonary Surfactant Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 33. Italy Pulmonary Surfactant Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 34. Russia Pulmonary Surfactant Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 35. Spain Pulmonary Surfactant Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 36. Netherlands Pulmonary Surfactant Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 37. Switzerland Pulmonary Surfactant Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 38. Sweden Pulmonary Surfactant Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 39. Poland Pulmonary Surfactant Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 40. Asia Pacific Pulmonary Surfactant Market Size by Country in 2024
- Figure 41. Asia Pacific Pulmonary Surfactant Sales Market Share by Country (2020-2031)
- Figure 42. Asia Pacific Pulmonary Surfactant Revenue Market Share by Country (2020-2031)
- Figure 43. China Pulmonary Surfactant Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 44. Japan Pulmonary Surfactant Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 45. South Korea Pulmonary Surfactant Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 46. India Pulmonary Surfactant Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 47. Australia Pulmonary Surfactant Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 48. Taiwan Pulmonary Surfactant Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 49. Southeast Asia Pulmonary Surfactant Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 50. Southeast Asia Pulmonary Surfactant Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 51. South America Pulmonary Surfactant Market Size by Country in 2024
- Figure 52. South America Pulmonary Surfactant Sales Market Share by Country (2020-2031)
- Figure 53. South America Pulmonary Surfactant Revenue Market Share by Country (2020-2031)
- Figure 54. Brazil Pulmonary Surfactant Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 55. Argentina Pulmonary Surfactant Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 56. Chile Pulmonary Surfactant Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 57. Middle East and Africa Pulmonary Surfactant Market Size by Country in 2024
- Figure 58. Middle East and Africa Pulmonary Surfactant Sales Market Share by Country (2020-2031)
- Figure 59. Middle East and Africa Pulmonary Surfactant Revenue Market Share by Country (2020-2031)
- Figure 60. Egypt Pulmonary Surfactant Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 61. South Africa Pulmonary Surfactant Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 62. Israel Pulmonary Surfactant Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 63. Türkiye Pulmonary Surfactant Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 64. GCC Countries Pulmonary Surfactant Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 65. Global Pulmonary Surfactant Sales Market Share by Type (2020-2031)
- Figure 66. Global Pulmonary Surfactant Revenue Market Share by Type (2020-2031)
- Figure 67. Global Pulmonary Surfactant Price (US$/unit) by Type (2020-2031)
- Figure 68. Global Pulmonary Surfactant Sales Market Share by Application (2020-2031)
- Figure 69. Global Pulmonary Surfactant Revenue Market Share by Application (2020-2031)
- Figure 70. Global Pulmonary Surfactant Price (US$/unit) by Application (2020-2031)
- Figure 71. Pulmonary Surfactant Value Chain
- Figure 72. Pulmonary Surfactant Production Mode & Process
- Figure 73. Direct Comparison with Distribution Share
- Figure 74. Distributors Profiles
- Figure 75. Pulmonary Surfactant Industry Opportunities and Challenges
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
